Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Current Liabilities (2016 - 2025)

Capricor Therapeutics has reported Total Current Liabilities over the past 15 years, most recently at $35.8 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $35.8 million for Q4 2025, up 70.44% from a year ago — trailing twelve months through Dec 2025 was $35.8 million (up 70.44% YoY), and the annual figure for FY2025 was $35.8 million, up 70.44%.
  • Total Current Liabilities for Q4 2025 was $35.8 million at Capricor Therapeutics, up from $28.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CAPR hit a ceiling of $37.1 million in Q1 2023 and a floor of $3.0 million in Q3 2021.
  • Median Total Current Liabilities over the past 5 years was $22.8 million (2022), compared with a mean of $21.8 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 676.18% in 2022 and later crashed 37.81% in 2024.
  • Capricor Therapeutics' Total Current Liabilities stood at $4.1 million in 2021, then soared by 470.63% to $23.6 million in 2022, then surged by 32.57% to $31.3 million in 2023, then tumbled by 32.76% to $21.0 million in 2024, then soared by 70.44% to $35.8 million in 2025.
  • The last three reported values for Total Current Liabilities were $35.8 million (Q4 2025), $28.1 million (Q3 2025), and $28.4 million (Q2 2025) per Business Quant data.